Compare NUVL & CHRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUVL | CHRD |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | 676 |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 8.2B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | CHRD |
|---|---|---|
| Price | $123.50 | $116.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 13 |
| Target Price | $134.75 | ★ $149.17 |
| AVG Volume (30 Days) | ★ 4.2M | 751.6K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 3.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.56 |
| Revenue Next Year | $1,239.49 | N/A |
| P/E Ratio | ★ N/A | $34.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.14 | $84.25 |
| 52 Week High | $123.69 | $151.95 |
| Indicator | NUVL | CHRD |
|---|---|---|
| Relative Strength Index (RSI) | 66.42 | 29.84 |
| Support Level | $97.99 | $86.73 |
| Resistance Level | $123.62 | $127.56 |
| Average True Range (ATR) | 0.58 | 4.11 |
| MACD | 0.66 | -1.55 |
| Stochastic Oscillator | 99.45 | 3.31 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.